Matulonis U - Search Results

1

Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival.

Clauss A, Ng V, Liu J, Piao H, Russo M, Vena N, Sheng Q, Hirsch MS, Bonome T, Matulonis U, Ligon AH, Birrer MJ, Drapkin R. Clauss A, et al. Among authors: matulonis u. Neoplasia. 2010 Feb;12(2):161-72. doi: 10.1593/neo.91542. Neoplasia. 2010. PMID: 20126474 Free PMC article.

2

Rational use of cytotoxic chemotherapy for recurrent ovarian cancer.

Liu J, Matulonis U. Liu J, et al. Among authors: matulonis u. J Natl Compr Canc Netw. 2006 Oct;4(9):947-53. doi: 10.6004/jnccn.2006.0078. J Natl Compr Canc Netw. 2006. PMID: 17020671 Review.

3

Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.

Callahan MJ, Nagymanyoki Z, Bonome T, Johnson ME, Litkouhi B, Sullivan EH, Hirsch MS, Matulonis UA, Liu J, Birrer MJ, Berkowitz RS, Mok SC. Callahan MJ, et al. Clin Cancer Res. 2008 Dec 1;14(23):7667-73. doi: 10.1158/1078-0432.CCR-08-0479. Clin Cancer Res. 2008. PMID: 19047092 Free PMC article.

4

Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.

Liu JF, Hirsch MS, Lee H, Matulonis UA. Liu JF, et al. Gynecol Oncol. 2009 Dec;115(3):401-6. doi: 10.1016/j.ygyno.2009.08.023. Epub 2009 Sep 30. Gynecol Oncol. 2009. PMID: 19796795

5

Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer.

Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN. Campos SM, et al. Among authors: matulonis u. Int J Clin Oncol. 2010 Aug;15(4):390-8. doi: 10.1007/s10147-010-0073-6. Epub 2010 Apr 20. Int J Clin Oncol. 2010. PMID: 20405155 Clinical Trial.

6

New advances in ovarian cancer.

Liu J, Matulonis UA. Liu J, et al. Oncology (Williston Park). 2010 Jul;24(8):721-8. Oncology (Williston Park). 2010. PMID: 20718251 Free article. Review.

7

High throughput interrogation of somatic mutations in high grade serous cancer of the ovary.

Matulonis UA, Hirsch M, Palescandolo E, Kim E, Liu J, van Hummelen P, MacConaill L, Drapkin R, Hahn WC. Matulonis UA, et al. PLoS One. 2011;6(9):e24433. doi: 10.1371/journal.pone.0024433. Epub 2011 Sep 8. PLoS One. 2011. PMID: 21931712 Free PMC article.

8

Anti-angiogenic agents in ovarian cancer: dawn of a new era?

Liu J, Matulonis UA. Liu J, et al. Curr Oncol Rep. 2011 Dec;13(6):450-8. doi: 10.1007/s11912-011-0194-8. Curr Oncol Rep. 2011. PMID: 21993845 Review.

9

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.

Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, McConkey DJ, Sallan SE, Silverman L, Hirsch MS, Carrasco DR, Letai A. Ni Chonghaile T, et al. Science. 2011 Nov 25;334(6059):1129-33. doi: 10.1126/science.1206727. Epub 2011 Oct 27. Science. 2011. PMID: 22033517 Free PMC article.

10

Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer.

Bentink S, Haibe-Kains B, Risch T, Fan JB, Hirsch MS, Holton K, Rubio R, April C, Chen J, Wickham-Garcia E, Liu J, Culhane A, Drapkin R, Quackenbush J, Matulonis UA. Bentink S, et al. PLoS One. 2012;7(2):e30269. doi: 10.1371/journal.pone.0030269. Epub 2012 Feb 13. PLoS One. 2012. PMID: 22348002 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

322 results

Search Page